[go: up one dir, main page]

WO2023121334A1 - Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire - Google Patents

Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire Download PDF

Info

Publication number
WO2023121334A1
WO2023121334A1 PCT/KR2022/021047 KR2022021047W WO2023121334A1 WO 2023121334 A1 WO2023121334 A1 WO 2023121334A1 KR 2022021047 W KR2022021047 W KR 2022021047W WO 2023121334 A1 WO2023121334 A1 WO 2023121334A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
radish
respiratory diseases
composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/021047
Other languages
English (en)
Korean (ko)
Inventor
성윤영
김동선
손은정
육흥주
이윤미
김영숙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2023121334A1 publication Critical patent/WO2023121334A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction

Definitions

  • the present invention relates to a composition for the prevention, improvement or treatment of respiratory diseases containing an extract of Dorado radish as an active ingredient.
  • Asthma chronic obstructive pulmonary disease, allergic rhinitis, cough, cough, acute and chronic bronchitis, bronchiolitis, sore throat, tonsillitis, laryngitis, etc. are typical respiratory diseases.
  • Asthma refers to chronic inflammation of the airways, particularly the bronchi. Inflammation caused by asthma can be aggravated by a wide variety of factors such as smoke, allergens, cold wind, exercise, and respiratory infections, and continuous inflammation causes airway deformation and airway hyper-responsiveness. Due to these causes, common symptoms such as wheezing (a symptom in which the airway is narrowed and wheezing or purring breath sounds appear), shortness of breath, coughing, and excessive sputum discharge appear.
  • wheezing a symptom in which the airway is narrowed and wheezing or purring breath sounds appear
  • shortness of breath, coughing, and excessive sputum discharge appear.
  • the respiratory tract is largely composed of a mucous membrane and a muscle called bronchial smooth muscle, and there are many glands in the mucous membrane that continuously secrete necessary secretions.
  • the bronchial smooth muscle contracts, the respiratory airway narrows.
  • an inflammatory reaction occurs due to a wide variety of factors such as smoke, allergens, cold wind, exercise, and respiratory infections, the secretion from the glands further increases, and this secretion blocks the airway, causing the mucous membrane to swell into the airway, further narrowing the airway. .
  • paroxysmal coughing accompanied by wheezing and difficulty in breathing appear severely, and during seizures, dry cough occurs and chest pressure is felt.
  • asthmatic patients who have only symptoms of chronic cough and chest tightness without wheezing and unexplained dyspnea, but these symptoms tend to appear suddenly and paroxysmal during daily life.
  • cardamine flexuosa grows near rice fields and in wetlands. Branches diverge and spread from the bottom, 10 to 30 cm high, and the lower part has hairs and is black purple.
  • the leaves are alternate and pinnate compound leaves. There are 7 to 17 small leaves, egg-shaped or broad egg-shaped, and the small leaf at the end is the largest. Flowers bloom in April- May, are white, and about 20 flowers run in raceme. It has about 10 cross-shaped flowers. There are 4 calyxes, black purple, and petals are twice as long as calyxes. It looks like an upside-down egg in the shape of a petal.
  • Korean Patent Publication No. 2021-0145578 discloses a cosmetic composition for moisturizing skin containing an extract of Stork radish. There is no mention of a preventive, ameliorative or therapeutic composition.
  • the present invention has been derived from the above needs, and the present invention provides a composition for preventing, improving or treating respiratory diseases containing a storus radish extract as an active ingredient, and the stor radish extract is a respiratory cell, bronchial epithelial cell. It reduces the production of chemokine RANTES, a mediator of inflammation, and reduces the expression of inflammatory cytokines (IL-6, TNF- ⁇ and MUC5AC).
  • the present invention provides a health functional food composition for preventing or improving respiratory diseases containing a storus extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of respiratory diseases containing a dorado extract as an active ingredient.
  • the present invention provides a veterinary composition for the prevention or treatment of respiratory diseases containing a storus extract as an active ingredient.
  • the present invention provides a feed additive for preventing or improving respiratory diseases containing the extract of radish radish as an active ingredient.
  • the present invention relates to a composition for preventing, ameliorating or treating respiratory diseases containing a storus extract as an active ingredient.
  • a composition for preventing, ameliorating or treating respiratory diseases containing a storus extract as an active ingredient not only has the effect of reducing the expression level of inflammatory cytokines (IL-6, TNF- ⁇ and MUC5AC), but also reduces the total number of BAL cells and the number of neutrophils in BAL in animal models, IL-1 ⁇ and TNF in BALF It has the effect of reducing the content of - ⁇ , IL-17, MIP2, and CXCL-1, and the expression level of TNF- ⁇ , MIP2, CXCL-1, and MUC5AC genes, and has the effect of inhibiting lung tissue damage.
  • Figure 1 is a result of confirming the RANTES production rate according to the treatment of dorado radish extract in bronchial epithelial cells (BEAS-2B).
  • Dexa is a positive control group treated with 0.5 ⁇ M of dexamethasone.
  • ### indicates a statistically significant increase in the RANTES production rate in the 10ng/ml TNF- ⁇ treated group compared to the control group, p ⁇ 0.001, and *** indicates a 10ng/ml TNF- ⁇ treated group It means that the rate of RANTES production in the contrast radish radish extract treatment group and the positive control group (Dexa) decreased statistically significantly, p ⁇ 0.001.
  • Figure 2 is the result of confirming the change in the expression level of the inflammatory cytokine IL-6 after inducing inflammation with LPS in bronchial epithelial cells.
  • ### indicates a statistically significant increase in the IL-6 expression level of the LPS-treated group (LPS20) compared to the control (normal control), p ⁇ 0.001, and *** indicates that the LPS group compared to the present invention 50 ⁇ g / ml , p ⁇ 0.001, indicating that the IL-6 expression level of the radish radish extract treatment group (CF50) decreased statistically significantly.
  • Figure 3 is the result of confirming the change in the expression level of the inflammatory cytokine TNF- ⁇ after inducing inflammation with LPS in bronchial epithelial cells.
  • ### indicates a statistically significant increase in TNF- ⁇ expression level in the LPS-treated group (LPS20) compared to the Control (normal control group), p ⁇ 0.001, and *** is 50 ⁇ g/ml of the present invention compared to the LPS group , p ⁇ 0.001, indicating that the TNF- ⁇ expression level of the radish radish extract treatment group (CF50) decreased statistically significantly.
  • Figure 4 is the result of confirming the change in the expression level of the inflammatory cytokine MUC5AC after inducing inflammation with LPS in bronchial epithelial cells.
  • ### indicates a statistically significant increase in MUC5AC expression level in the LPS-treated group (LPS20) compared to the Control (normal control group), p ⁇ 0.001, and ** indicates that 50 ⁇ g/ml of the present invention compared to the LPS group It means that the MUC5AC expression level of the extract treatment group decreased statistically significantly, p ⁇ 0.01.
  • Figure 5 is a schematic diagram showing an experimental schedule for confirming the effect of the storus radish extract of the present invention using a respiratory injury animal model.
  • Figure 6 is a result of confirming the total number of BAL cells after administering the storus extract of the present invention to a respiratory injury animal model.
  • ### indicates a statistically significant increase in the total number of BAL cells in the respiratory injury control group induced by LPS + CS (standard tobacco extract) compared to the normal group, p ⁇ 0.001, **, *** are compared to the control group
  • the total number of BAL cells in the radish radish extract administration group or the positive control group of the present invention was statistically significantly decreased, ** is p ⁇ 0.01, and *** is p ⁇ 0.001.
  • Figure 9 shows the results of confirming the expression levels of TNF- ⁇ , MIP2, CXCL-1, and MUC5AC genes in lung tissues after administering the wild horseradish extract of the present invention to a respiratory injury animal model.
  • ##, ### indicate a statistically significant increase in the expression levels of TNF- ⁇ , MIP2, CXCL-1, and MUC5AC genes in the lung tissue of the control group with respiratory injury induced by LPS+CS (standard tobacco extract) compared to the normal group.
  • ## is p ⁇ 0.01
  • ### is p ⁇ 0.001.
  • FIG. 10 shows the results of H&E staining and M-T staining confirming the inhibition of pathological damage to lung tissue after administering the extract of the present invention to a respiratory injury animal model.
  • the present invention relates to a health functional food composition for preventing or improving respiratory diseases containing an extract of Dorado radish as an active ingredient.
  • the respiratory disease is preferably selected from the group consisting of asthma, chronic obstructive pulmonary disease, bronchitis, sore throat, tonsillitis and laryngitis, but is not limited thereto.
  • the extract of Stork radish is extracted from the outpost of Stork radish, but is not limited thereto, and may be used by adopting a specific part as needed.
  • the raspberry extract may be prepared by a method comprising the following steps, but is not limited thereto:
  • step (3) preparing an extract by drying the filtered extract of step (2).
  • the extraction solvent is preferably selected from water, C 1 ⁇ C 4 lower alcohol or mixtures thereof, more preferably water or ethanol, and still more preferably ethanol, but is not limited thereto.
  • the extraction method all conventional methods known in the art such as hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used. It is preferable to extract the extraction solvent by adding 1 to 20 times the weight of the horseradish.
  • the extraction temperature is preferably 20 to 100 ° C, but is not limited thereto.
  • the extraction time is preferably 1 to 5 hours, more preferably 1 to 3 hours, but is not limited thereto.
  • drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, more preferably freeze drying, but not limited thereto.
  • the health functional food composition is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.
  • the health functional food composition of the present invention may be prepared by adding the extract of Dorsal japonica as it is or mixing it with other foods or food ingredients, and may be appropriately prepared according to a conventional method.
  • foods to which the radish radish extract can be added include caramel, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, It may be in the form of any one selected from tea, drinks, alcoholic beverages and vitamin complexes, and includes all health functional foods in the conventional sense.
  • the health functional food composition includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. It may also contain fruit flesh for the preparation of natural fruit juices and vegetable beverages. The above components may be used independently or in combination.
  • the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional components, and the natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, dextrin, and cyclosaccharides. polysaccharides such as dextrin, sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the ratio of the natural carbohydrates is not very important, but is preferably 0.01 to 0.04 g, more preferably 0.02 to 0.03 g, with respect to 100 g of the composition of the present invention, but is not limited thereto.
  • natural sweeteners such as thaumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame may be used.
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of respiratory diseases containing the extract of radish radish as an active ingredient.
  • the pharmaceutical composition containing the extract of Dorado radishes according to the present invention is preferably in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups and aerosols, but is not limited thereto.
  • a pharmaceutically acceptable carrier, excipient or diluent may be further included, and carriers, excipients or diluents that may be included in the pharmaceutical composition containing the raspberry extract include lactose, dextrose, sucrose , oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate , propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the pharmaceutical composition containing the extract of the radish radish of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 10 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
  • the present invention relates to a veterinary composition for the prevention or treatment of respiratory diseases containing the extract of Dorado radish as an active ingredient.
  • the veterinary composition of the present invention may further include appropriate excipients and diluents according to conventional methods.
  • Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate , polysorbate 60, methylparaben, propylparaben and mineral oil.
  • the veterinary composition according to the present invention may further include fillers, anti-agglomerating agents, lubricants, wetting agents, spices, emulsifiers, preservatives, and the like. Or it may be formulated using a method well known in the art to provide delayed release, and the dosage form may be a powder, granule, tablet, capsule, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, It may be in the form of a suppository, a sterile injection solution, or a sterile external preparation. An effective amount of the veterinary composition according to the present invention can be appropriately selected according to the individual animal.
  • the present invention relates to a feed additive for the prevention or improvement of respiratory diseases containing a storus radish extract as an active ingredient.
  • the feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.
  • the term 'feed' may mean any natural or artificial diet, one meal, etc., or a component of the one meal meal, for or suitable for the animal to eat, ingest, and digest.
  • the type of feed is not particularly limited, and feeds commonly used in the art may be used.
  • Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.
  • the inhibitory activity of the inflammatory chemokine, RANTES was evaluated using human bronchial epithelial cell lines.
  • BEAS-2B human bronchial epithelial cell, ATCC, USA
  • DMEM Dulbecco's modified eagle's medium
  • FBS fetal bovine serum
  • PS penicillin-streptomycin
  • the amount of RANTES secretion was measured according to the manufacturer's method using an ELISA kit (R&D systems, USA) to measure the amount of RANTE secretion present in the cell supernatant. Statistical differences were assessed for significance using Student's t-test.
  • the amount of RANTES production was statistically significantly increased in the TNF- ⁇ treatment group compared to the control group (Control), and in contrast to this, the group treated with the radish radish extract of the present invention and the positive control group (Dexa) In , RANTES production was statistically significantly reduced.
  • Example 3 After inducing inflammation with LPS in bronchial epithelial cells, inflammatory cytokines IL-6, TNF- ⁇ , mucus secretion protein MUC5AC expression level change confirmation
  • BEAS-2B human bronchial epithelial cell, ATCC, USA
  • cells a human bronchial epithelial cell line
  • PS penicillin-streptomycin
  • the medium was replaced, and cultured for 24 hours by treating with 50 ⁇ g/ml of Stork radish extract and 20 ⁇ g/ml of LPS. After 24 hours, the cell supernatant was recovered and the expression levels of IL-6, TNF- ⁇ and MUC5AC were measured.
  • COPD chronic obstructive pulmonary disease
  • LPS+CS standard tobacco extract
  • the experimental group was a normal group without any treatment, a control group treated with a COPD inducer, a COPD inducer and a positive control dexamethasone (3mg/kg) administered group, a COPD inducer and a radish extract (200mg/kg)
  • the administration group (CF 200) and the COPD inducer and radish radish extract (100 mg/kg) administration group (CF 100) were selected.
  • the drug was administered orally every day for 14 days, and after the experiment, mouse alveolar lavage fluid (BALF) and lung tissue of each experimental group were separated (FIG. 5).
  • BALF bronchoalveolar lavage fluid
  • ELISA was performed to measure the amounts of IL-1 ⁇ , TNF- ⁇ , IL-17, MIP2, and CXCL-1 in BALF. After the capture antibody was added, and overnight at 4° C., the cells were washed 4 times with a washing buffer. 100 ⁇ l of biotin-conjugated antibody reagent was treated in each well, reacted at room temperature for 1 hour, washed twice, and then treated with 100 ⁇ l of streptavidin-HRP solution in each well and incubated at room temperature for 1 hour After the reaction, it was washed twice with a washing buffer solution. Here, 100 ⁇ l of the substrate solution was treated and reacted for 20 minutes, and then the reaction was terminated by treatment with 50 ⁇ l of the reaction stop solution, and the absorbance was measured at 450 nm.
  • IL-1 ⁇ , TNF- ⁇ , IL-17, MIP2, and CXCL-1 which are inflammation-related cytokines and chemokines, in BALF were all increased in the LPS+CS (standard tobacco extract) induced control group. There was a statistically significant decrease in the control group and the radish radish extract (CF)-administered group (FIG. 8).
  • RNA extraction solution was added and ground until dissolved. After centrifugation at 13,000 rpm, RNA was extracted by washing with ethanol and drying. The extracted RNA was used for first strand cDNA synthesis.
  • Real-time polymerization of the synthesized cDNA was carried out using an Applied Biosystem 7500 Real-Time PCR system (Applied Biosystems, USA). TNF- ⁇ , MIP2, CXCL-1, MUC5AC primers were used, and G3PDH probe (VIC, Applied Biosystems, USA) was used. Real-time polymerization chain reaction conditions were pre-denaturation at 50 °C for 2 minutes, 94 °C for 10 minutes, and 40 cycles at 95 °C for 0.15 minutes and 60 °C for 1 minute. RQ (relative quantitative) was calculated using G3PDH as an internal standard for the radish radish extract administration group and the control group.
  • the lung tissue was cut and fixed in 10% neutral-buffered formalin for 24 hours, then dehydrated with alcohol, embedded in paraffin to make a block, and then 4 ⁇ m with a microtome. Thick tissue sections were prepared and H&E (Hematoxylin & Eosin) staining, M-T (Masson-Trichrome) staining, collagen deposition staining, and PAS staining were performed to observe goblet cells and secreted mucus. After staining, it was observed through an optical microscope (Nikon, Japan) at 400 ⁇ magnification.
  • Results were reported as mean ⁇ error, and significance was determined using Duncan's multiple comparison analysis method (SPSS statistics version 19.0 statistic software, Inc, IBM, USA) followed by Student's t-test and one-way ANOVA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de Cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire. L'extrait de Cardamine flexuosa a pour effet de réduire la production de chimiokine RANTES qui est un médiateur induisant une inflammation, à partir de cellules épithéliales bronchiques qui sont des cellules respiratoires, et peut ainsi être avantageusement utilisé en tant qu'alicament, en tant que médicament ou en tant qu'additif alimentaire contre des maladies respiratoires, notamment l'asthme ou la broncho-pneumopathie chronique obstructive (BPCO).
PCT/KR2022/021047 2021-12-23 2022-12-22 Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire Ceased WO2023121334A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0186404 2021-12-23
KR20210186404 2021-12-23

Publications (1)

Publication Number Publication Date
WO2023121334A1 true WO2023121334A1 (fr) 2023-06-29

Family

ID=86903147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/021047 Ceased WO2023121334A1 (fr) 2021-12-23 2022-12-22 Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire

Country Status (2)

Country Link
KR (1) KR20230098053A (fr)
WO (1) WO2023121334A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195534A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤
JP2011195533A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd 線維芽細胞増殖促進剤および抗老化剤
KR101863731B1 (ko) * 2017-05-18 2018-06-01 충남대학교산학협력단 큰황새냉이 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물
KR20210120422A (ko) * 2020-03-26 2021-10-07 애경산업(주) 꽃황새냉이 추출물을 포함하는 피부 보습용 화장료 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195534A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤
JP2011195533A (ja) * 2010-03-23 2011-10-06 Shiseido Co Ltd 線維芽細胞増殖促進剤および抗老化剤
KR101863731B1 (ko) * 2017-05-18 2018-06-01 충남대학교산학협력단 큰황새냉이 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물
KR20210120422A (ko) * 2020-03-26 2021-10-07 애경산업(주) 꽃황새냉이 추출물을 포함하는 피부 보습용 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Edible wild grass/stork horseradish", TRMAN'S BLOG, 28 February 2020 (2020-02-28), XP093074493, Retrieved from the Internet <URL:https://m.blog.naver.com/trman/221807807660> [retrieved on 20230817] *

Also Published As

Publication number Publication date
KR20230098053A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
WO2022050516A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d&#39;elaeocarpus sylvestris en tant que principe actif
WO2019189992A1 (fr) Composition pour prévenir, soulager ou traiter des maladies inflammatoires, contenant de l&#39;huile de zanthoxylum schinifolium en tant que principe actif
WO2023287151A1 (fr) Composition pour la prévention, le soulagement ou le traitement de maladies respiratoires, comprenant un extrait de centella asiatica fermentée en tant que principe actif
WO2023121334A1 (fr) Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l&#39;atténuation ou le traitement d&#39;une maladie respiratoire
KR20240158405A (ko) 소청룡탕 에탄올 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2023195644A1 (fr) Composition de prévention, d&#39;amélioration ou de traitement de l&#39;asthme contenant un extrait de malus baccata var. mandshurica comme principe actif
WO2023121331A1 (fr) Composition destinée à la prévention, à l&#39;amélioration ou au traitement d&#39;une maladie respiratoire contenant un extrait de lysimachia mauritiana en tant que principe actif
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
WO2020027574A1 (fr) Composition permettant de prévenir, d&#39;atténuer ou de traiter des maladies respiratoires, contenant un extrait de siraitia grosvenorii en tant que principe actif
WO2022124803A1 (fr) Composition destinée à la prévention, au soulagement ou au traitement de maladies allergiques, comprenant un extrait de spatholobus suberectus en tant que principe actif
KR20230096889A (ko) 담배풀속 식물 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
KR102894756B1 (ko) 절패모 추출물을 유효성분으로 포함하는 면역증진 및 염증성 장질환의 예방, 개선 또는 치료용 조성물
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l&#39;atténuation ou le traitement du syndrome d&#39;hypogonadisme d&#39;apparition tardive
KR102819680B1 (ko) 백두옹 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2015122728A1 (fr) Composition anti-tuberculose pour le traitement et la prévention de la tuberculose comprenant un extrait ou de melia azedarach l. ou un extrait de lobelia chinensis lour et des fractions de ceux-ci
WO2021085741A1 (fr) Composition d&#39;amélioration ou de traitement de la maladie d&#39;alzheimer comprenant comme principe actif du tetragonia tetragonioides
KR102671544B1 (ko) 복합 한약재 추출물을 유효성분으로 포함하는 스트레스 완화 및 면역증진용 조성물
WO2023204364A1 (fr) Composition permettant la prévention, l&#39;amélioration ou le traitement de maladies respiratoires allergiques comprenant un extrait d&#39;alpinia officinarum hance en tant que principe actif
KR20230096888A (ko) 게박쥐나물 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2012067322A1 (fr) Composition pharmaceutique destinée au traitement de l&#39;asthme contenant des acides 4‑phénylbutyriques ou leurs sels pharmaceutiquement acceptables en tant que principe actif
WO2023243855A1 (fr) Composition comprenant un extrait de daihong crataegus pinnatifida bunge en tant que principe actif pour améliorer la santé intestinale ou traiter une maladie intestinale inflammatoire
WO2025121967A1 (fr) Composition pour le traitement de maladies respiratoires comprenant un extrait de feuilles de perilla
WO2025234773A1 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif
WO2025221099A1 (fr) Composition destinée à renforcer la force musculaire ou à prévenir, améliorer ou traiter la perte musculaire comprenant un extrait de lilium lancifolium en tant que principe actif
WO2023048504A1 (fr) Composition pour prévenir ou traiter des maladies associées à une faiblesse musculaire ou une sarcopénie, contenant un extrait de rosa davurica pallas en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22911967

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22911967

Country of ref document: EP

Kind code of ref document: A1